Iambic Therapeutics' Co-Founder and CEO on this month's $50M Series B Extension and the company's AI driven pipeline

blonca9
Jun 24, 2024
1 min read

Tom Miller describes the rationale for the raise and what it will allow Iambic to do, how he believes the company's AI approach is unique, the lead Her-2 program, and what's behind it.

Recent Posts

See All

On its 10-year anniversary, Arcus Biosciences is taking its 4th molecule into pivotal studies. Co-Founder & CEO Terry Rosen talks HIF-2⍺, TIGIT, and CD73

Siren Biotechnology is using an online platform to raise up to $5 million from the public in a "community round" - it might be a new avenue of funding for biotech companies

Theravance Biopharma has a key pivotal trial readout scheduled for late '25 / early '26 in symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA)

Iambic Therapeutics' Co-Founder and CEO on this month's $50M Series B Extension and the company's AI driven pipeline

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight